BioNTech SE revenue for the last year amounted to 4.22 B USD, the most of which — 4.13 B USD — came from its highest performing source at the moment, Immunotherapy Technologies, the year earlier bringing 18.19 B USD. The greatest contribution to the revenue figure was made by United States — last year it brought BioNTech SE 3.26 B USD, and the year before that — 13.36 B USD.